Novo Nordisk A/S $NVO Stock Holdings Raised by Hohimer Wealth Management LLC

Hohimer Wealth Management LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 59.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 139,895 shares of the company’s stock after acquiring an additional 52,231 shares during the quarter. Hohimer Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $5,303,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of NVO. CoreCap Advisors LLC grew its position in shares of Novo Nordisk A/S by 4.7% during the second quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock worth $256,000 after acquiring an additional 242 shares during the last quarter. Claro Advisors Inc. raised its position in Novo Nordisk A/S by 1.2% in the 3rd quarter. Claro Advisors Inc. now owns 21,868 shares of the company’s stock valued at $829,000 after purchasing an additional 256 shares during the last quarter. Carson Advisory Inc. raised its position in Novo Nordisk A/S by 2.2% in the 1st quarter. Carson Advisory Inc. now owns 12,316 shares of the company’s stock valued at $453,000 after purchasing an additional 268 shares during the last quarter. Byrne Asset Management LLC boosted its stake in Novo Nordisk A/S by 9.7% during the 3rd quarter. Byrne Asset Management LLC now owns 3,055 shares of the company’s stock worth $114,000 after purchasing an additional 270 shares during the period. Finally, Bradley Foster & Sargent Inc. CT boosted its stake in Novo Nordisk A/S by 0.6% during the 1st quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company’s stock worth $1,726,000 after purchasing an additional 272 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 0.2%

NYSE:NVO opened at $40.37 on Monday. The firm has a market cap of $180.26 billion, a P/E ratio of 10.17, a PEG ratio of 1.38 and a beta of 0.70. The company has a current ratio of 0.84, a quick ratio of 0.64 and a debt-to-equity ratio of 0.54. The stock’s 50 day simple moving average is $40.58 and its 200-day simple moving average is $43.86. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on NVO. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. DZ Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, UBS Group reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Five equities research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have given a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus price target of $59.44.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Growth outlook and Wegovy pill adoption: Novo raised its 2026 outlook as its GLP-1 portfolio continued to grow, with accelerating Wegovy pill adoption and strong patient additions. The company also expects to expand the pill’s availability to more than 20 markets by mid-2027. NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook Novo Nordisk: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: More evidence for Wegovy beyond obesity: New retrospective real-world studies reported associations between Wegovy 2.4 mg use in adults with MASH and reductions in liver enzymes, weight and blood sugar. The findings could broaden the drug’s potential market, though the study design shows associations rather than proving cause and effect. Novo real-world studies link Wegovy to reductions in liver enzymes, weight, and blood sugar
• Positive Sentiment: Pipeline and valuation support: A report highlighted 12.4% weight loss in a trial of a pipeline drug, while one bullish analyst argued that Novo’s valuation and oral GLP-1 opportunity offer upside. These are potential catalysts, but depend on further clinical and commercial execution. Pipeline drug trial reports 12.4% weight loss
• Neutral Sentiment: Near-term catalysts: Investors are also watching an expected FDA decision and upcoming industry presentations, which could provide direction but add uncertainty until outcomes are known. Novo Nordisk’s Next Act Hinges on Two Clocks
• Negative Sentiment: Profitability and competition remain concerns: Q3 revenue was DKK 79.2 billion, but net income was DKK 16.7 billion, and reports characterized the results as a profit squeeze despite the raised outlook. Generic pressure in Brazil and pricing concerns could constrain margins and future growth. Novo Nordisk Stock Faces Q3 Earnings Profit Squeeze Leadership Reshuffle and Generic Pressure in Brazil

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus.

The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world.

Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.